Targretin(bexarotene)
Bexarotene, Targretin (bexarotene) is a small molecule pharmaceutical. Bexarotene was first approved as Targretin on 1999-12-29. It is used to treat t-cell lymphoma cutaneous in the USA. It has been approved in Europe to treat t-cell lymphoma cutaneous. The pharmaceutical is active against retinoic acid receptor RXR-gamma, retinoic acid receptor RXR-alpha, and retinoic acid receptor RXR-beta. In addition, it is known to target peroxisome proliferator-activated receptor gamma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Bexarotene, Targretin (discontinued: Bexarotene)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bexarotene
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TARGRETIN | Bausch Health Companies | N-021055 RX | 1999-12-29 | 1 products, RLD, RS |
| TARGRETIN | Bausch Health Companies | N-021056 RX | 2000-06-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bexarotene | ANDA | 2025-10-13 |
| targretin | New Drug Application | 2020-04-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| t-cell lymphoma cutaneous | — | D016410 | C84.A |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 2 | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | — | 1 |
| Thyroid diseases | D013959 | — | E00-E07 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bexarotene |
| INN | bexarotene |
| Description | Bexarotene is a retinoid, a member of benzoic acids and a member of naphthalenes. It has a role as an antineoplastic agent. |
| Classification | Small molecule |
| Drug class | arotinoid derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C |
Identifiers
| PDB | — |
| CAS-ID | 153559-49-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1023 |
| ChEBI ID | 50859 |
| PubChem CID | 82146 |
| DrugBank | DB00307 |
| UNII ID | A61RXM4375 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,980 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bexarotene, Targretin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,142 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use